1
|
Minami D, Kayatani H, Sato K, Fujiwara K, Shibayama T, Yonei T, Sato T. Clinical Characteristics of Severe Refractory Asthma Associated with the Effectiveness of Bronchial Thermoplasty. Acta Med Okayama 2019; 73:155-160. [PMID: 31015750 DOI: 10.18926/amo/56651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
We investigated the clinical characteristics of refractory asthma associated with the effectiveness of bronchial thermoplasty (BT). We retrospectively evaluated data from 10 patients who underwent BT between June 2016 and December 2017 at Okayama Medical Center. The following were measured before and 6 months post-BT: forced expiratory volume in 1.0 s (FEV1), fractional exhaled nitric oxide (FeNO), immunoglobulin E (IgE) level, blood eosinophil counts (Eosi), Asthma Quality of Life Questionnaire (AQLQ) score, and preventive medication use. At baseline, the mean post-bronchodilator FEV1 was 80.9% of the predicted value (range 45.6-115.7%). All patients were being treated with moderate- or high-dose inhaled corticosteroids and long-acting β2 agonists. The AQLQ improved from 4.26±1.67 at baseline to 5.59±0.94 at 6 months post-BT (p<0.05). The %FEV1, FeNO, IgE, and Eosi did not change significantly between baseline and 6 months post-BT. No severe complications were reported. BT was effective for non-allergic and non-eosinophilic in 3 patients, and allergic or eosinophilic in 4 patients. Their AQLQ improved by > 0.5 points post-BT. For both allergic and eosinophilic asthmatics following mepolizumab, BT was not useful. BT was effective for non-allergic and non-eosinophilic or allergic asthmatics, but insufficient for both allergic and eosinophilic following mepolizumab.
Collapse
Affiliation(s)
- Daisuke Minami
- Department of Respiratory Medicine, Okayama Medical Center, Okayama 701-1192,
| | | | | | | | | | | | | |
Collapse
|
2
|
Okawa S, Shibayama T, Shimonishi A, Nishimura J, Ozeki T, Takada K, Kayatani H, Minami D, Sato K, Fujiwara K, Yonei T, Sato T, Suno M. Success of Crizotinib Combined with Whole-Brain Radiotherapy for Brain Metastases in a Patient with Anaplastic Lymphoma Kinase Rearrangement-Positive Non-Small-Cell Lung Cancer. Case Rep Oncol 2019; 11:777-783. [PMID: 30627092 PMCID: PMC6323405 DOI: 10.1159/000492150] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Accepted: 07/17/2018] [Indexed: 12/22/2022] Open
Abstract
Although crizotinib shows marked antitumor activity in anaplastic lymphoma kinase (ALK) rearrangement-positive non-small-cell lung cancer (NSCLC) patients, all treated patients ultimately develop resistance to this drug. Isolated central nervous system failure without progression at extracranial sites is a common progression pattern in ALK rearrangement-positive NSCLC patients treated with crizotinib. Here, we report the success of crizotinib combined with whole-brain radiotherapy in an ALK rearrangement-positive NSCLC patient who developed leptomeningeal carcinomatosis and progression of multiple brain metastases. Additionally, we focused on the mechanism involved by examining the plasma and cerebrospinal fluid concentrations of crizotinib in the present case.
Collapse
Affiliation(s)
- Sachi Okawa
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Takuo Shibayama
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Atsushi Shimonishi
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Jun Nishimura
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Taichi Ozeki
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Kenji Takada
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Hiroe Kayatani
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Daisuke Minami
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Ken Sato
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Keiichi Fujiwara
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Toshiro Yonei
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Toshio Sato
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Manabu Suno
- Department of Oncology, Pharmaceutical Care and Sciences, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| |
Collapse
|
3
|
Minami D, Ando C, Nakasuka T, Iwamoto Y, Sato K, Fujiwara K, Shibayama T, Yonei T, Sato T. Usefulness of Bronchial Thermoplasty for Patients with a Deteriorating Lung Function. Intern Med 2018; 57:75-79. [PMID: 29033420 PMCID: PMC5799061 DOI: 10.2169/internalmedicine.8965-17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Accepted: 05/08/2017] [Indexed: 11/06/2022] Open
Abstract
Bronchial thermoplasty is a novel procedure for patients with severe asthma showing a stable lung function. We herein report two cases with a deteriorating lung function. The lung function tended to improve in one case, while the other case discontinued mepolizumab medication after the procedure. Treatment was performed safely under general anesthesia in both cases. The use of bronchial thermoplasty may therefore be useful for the treatment of patients with a deteriorating lung function.
Collapse
Affiliation(s)
- Daisuke Minami
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Chihiro Ando
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Takamasa Nakasuka
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Yoshitaka Iwamoto
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Ken Sato
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Keiichi Fujiwara
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Takuo Shibayama
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Toshiro Yonei
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Toshio Sato
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| |
Collapse
|
4
|
Minami D, Ando C, Sato K, Moriwaki K, Sugahara F, Nakasuka T, Iwamoto Y, Fujiwara K, Shibayama T, Yonei T, Sato T. Multiple Mucosa-associated Lymphoid Tissue Lymphoma of the Trachea. Intern Med 2017; 56:2907-2911. [PMID: 28943536 PMCID: PMC5709637 DOI: 10.2169/internalmedicine.8269-16] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Mucosa-associated lymphoid tissue lymphoma is a common type of primary pulmonary carcinoma, but the presence of polypoid nodules is extremely rare. We herein report two cases with multiple nodules in the trachea. One case involved polypoid nodules and airway stenosis mimicking asthma; the other case had concurrent nontuberculous mycobacterial infection. The diagnosis of both cases was confirmed by bronchoscopy. The two cases were sensitive to radiotherapy and chemotherapy, respectively.
Collapse
Affiliation(s)
- Daisuke Minami
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Chihiro Ando
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Ken Sato
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Kaori Moriwaki
- Department of Respiratory Medicine, Hiroshima City Asa Citizens Hospital, Japan
| | - Fumihiro Sugahara
- Department of Respiratory Medicine, Hiroshima City Asa Citizens Hospital, Japan
| | - Takamasa Nakasuka
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Yoshitaka Iwamoto
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Keiichi Fujiwara
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Takuo Shibayama
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Toshiro Yonei
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| | - Toshio Sato
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan
| |
Collapse
|
5
|
Makimoto G, Fujiwara K, Watanabe H, Kameyama N, Matsushita M, Rai K, Sato K, Yonei T, Sato T, Shibayama T. nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma. Case Rep Oncol 2014; 7:14-7. [PMID: 24575009 PMCID: PMC3934614 DOI: 10.1159/000357938] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
We present the case of a 40-year-old man with previously treated thymic carcinoma, complaining of gradually worsening back pain. Computed tomography scans of the chest showed multiple pleural disseminated nodules with a pleural effusion in the right thorax. The patient was treated with carboplatin on day 1 plus nab-paclitaxel on day 1 and 8 in cycles repeated every 4 weeks. Objective tumor shrinkage was observed after 4 cycles of this regimen. In addition, the elevated serum cytokeratin 19 fragment level decreased, and the patient's back pain was relieved without any analgesics. Although he experienced grade 4 neutropenia and granulocyte colony-stimulating factor (G-CSF) injection, the severity of thrombocytopenia and nonhematological toxicities such as reversible neuropathy did not exceed grade 1 during the treatment. To our knowledge, this is the first report to demonstrate the efficacy of combination chemotherapy consisting of carboplatin and nab-paclitaxel against thymic carcinoma. This case report suggests that nab-paclitaxel in combination with carboplatin can be a favorable chemotherapy regimen for advanced thymic carcinoma.
Collapse
Affiliation(s)
- Go Makimoto
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Keiichi Fujiwara
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Hiromi Watanabe
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Nobuhisa Kameyama
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Mizuho Matsushita
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Kammei Rai
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Ken Sato
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Toshiro Yonei
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Toshio Sato
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| | - Takuo Shibayama
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan
| |
Collapse
|
6
|
Kawahara M, Atagi S, Komuta K, Yoshioka H, Kawasaki M, Fujita Y, Yonei T, Ogushi F, Kubota K, Nogami N, Tsuchiya M, Shibata K, Tomizawa Y, Minato K, Fukuoka K, Asami K, Yamanaka T. Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer. Anticancer Res 2013; 33:4631-4637. [PMID: 24123041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
AIM Assessment of the efficacy of docetaxel plus carboplatin vs. paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Chemotherapy-naïve patients were randomly assigned at a ratio of 2 to 1 to receive six cycles of either docetaxel (60 mg/m(2)) plus carboplatin [area under the curve (AUC)=6 mg/ml min] or paclitaxel (200 mg/m(2)) plus carboplatin (same dose), on day 1 every 21 days. The primary end-point was progression-free survival (PFS). RESULTS A total of 90 patients were enrolled. Overall response rate, median PFS and median survival time in the docetaxel-plus-carboplatin group and the paclitaxel-plus-carboplatin group were 23% vs. 33%, 4.8 months vs. 5.1 months, and 17.6 months vs. 15.6 months, respectively. The docetaxel-plus-carboplatin group had a higher incidence of grade 3 or 4 neutropenia (88% vs. 60%). CONCLUSION Both regimens were similarly effective in Japanese patients with advanced NSCLC.
Collapse
|
7
|
Kayatani H, Matsuo K, Ueda Y, Matsushita M, Fujiwara K, Yonei T, Yamadori I, Shigematsu H, Andou A, Sato T. Pulmonary tumor thrombotic microangiopathy diagnosed antemortem and treated with combination chemotherapy. Intern Med 2012; 51:2767-70. [PMID: 23037471 DOI: 10.2169/internalmedicine.51.7682] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A 29-year-old man developed a persistent dry cough. Chest high-resolution computed tomography (HRCT) revealed centrilobular ultrafine granular shadows scattered in all lung fields. A lung biopsy with video-assisted thoracoscopic surgery revealed findings compatible with pulmonary tumor thrombotic microangiopathy (PTTM). However, the primary tumor was not identified. Combination chemotherapy with S-1 and cisplatin decreased his cough and improved the chest HRCT findings. The illness, however, gradually became difficult to control. He eventually developed pulmonary hypertension and died. Typically, an antemortem diagnosis of PTTM cannot be made. In this case, the diagnosis of PTTM and combination chemotherapy improved the chest HRCT findings, respiratory symptoms, and prognosis.
Collapse
Affiliation(s)
- Hiroe Kayatani
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Rai K, Fujiwara K, Tsushima M, Kudo K, Mizuta M, Matsuo K, Yonei T, Yamadori I, Kiura K, Sato T. A case of colorectal cancer with double-activating epidermal growth factor receptor mutations. Jpn J Clin Oncol 2011; 41:1138-41. [PMID: 21835826 DOI: 10.1093/jjco/hyr113] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
We describe the case of a 72-year-old woman with locally advanced lung tumor mimicking primary lung cancer. She was diagnosed with rectal cancer at the age of 65 years and was initially treated with platinum-based chemotherapy and thoracic irradiation as a treatment for primary lung cancer. One year later, a thyroid tumor was detected in her right thyroid lobe and was confirmed to have metastasized from rectal cancer based on pathological findings. Therefore, we suspected that she had metachronous double cancers and treated her with conventional chemotherapy for colorectal cancer. However, new life-threatening multiple lung metastases appeared. We treated her with the drug erlotinib because additional genetic analysis against primary lung tumor revealed typical double-activating epidermal growth factor receptor mutations. Histological review by immunostaining concluded that the primary lung tumor was composed of metastatic tumors from rectal cancer. In addition, genetic analysis revealed that the primary rectal cancer contained nearly the same types of double-activating epidermal growth factor receptor mutations as were present in the lung tumor. This is the first report of a case of rectal adenocarcinoma with double-activating epidermal growth factor receptor mutations.
Collapse
Affiliation(s)
- Kammei Rai
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu Kita-ku, Okayama 701-1192, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Wakatsuki M, Matsuo K, Kayatani H, Fujiwara K, Yonei T, Sato T. [A case of small cell lung cancer that presented with paraneoplastic syndrome]. Nihon Kokyuki Gakkai Zasshi 2011; 49:517-522. [PMID: 21842689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
A 65-year-old man had suffered from systemic erythema from November 2008 and had noticed gradually progressing weakness in the upper and lower limbs. He received medical treatment in another hospital but his symptoms did not improve. He was admitted to our hospital for treatment of diabetes in June 2009, and his chest X-ray images and CT scans showed a mass shadow in the right upper lobe with hilar and mediastinal lymphadenopathy. We performed bronchoscopy, and diagnosed small cell lung cancer (T2N2M1, stage IV). However, he had hand grip weakness and continuing upper and lower limb muscle weakness, and therefore electromyography was performed, which showed the presence of waxing in the right leg. Subsequently, a diagnosis of Lambert-Eaton myasthenic syndrome was made. As he also showed ataxia of the left lower extremity, we also diagnosed paraneoplastic cerebellar degeneration. We gave the patient chemotherapy consisting of carboplatin and etoposide which resulted in the disappearance of his waxing, and his grip strength and erythema immediately improved with regression of the tumor after 1 course of chemotherapy. We report a case of small cell lung cancer associated with Lambert-Eaton myasthenic syndrome, paraneoplastic cerebellar degeneration and erythema which presented as paraneoplastic syndrome, which improved with chemotherapy.
Collapse
Affiliation(s)
- Masatoshi Wakatsuki
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
| | | | | | | | | | | |
Collapse
|
10
|
Kudo K, Fujiwara K, Tsushima M, Mizuta M, Matsuo K, Yonei T, Sato T. Toxicity manifesting as cosmetic hair alterations during erlotinib treatment. Acta Oncol 2011; 50:146-8. [PMID: 20843170 DOI: 10.3109/0284186x.2010.509107] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
11
|
Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K, Tanimoto M. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010; 28:3299-306. [PMID: 20530281 DOI: 10.1200/jco.2009.24.7577] [Citation(s) in RCA: 191] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To demonstrate the efficacy of docetaxel and cisplatin (DP) chemotherapy with concurrent thoracic radiotherapy (TRT) for patients with locally advanced non-small-cell lung cancer (LA-NSCLC). PATIENTS AND METHODS Patients age 75 years or younger with LA-NSCLC, stratified by performance status, stage, and institution, were randomly assigned to two arms consisting of DP (docetaxel 40 mg/m(2) and cisplatin 40 mg/m(2) on days 1, 8, 29, and 36) or mitomycin, vindesine, and cisplatin (MVP) chemotherapy with concurrent TRT. RESULTS Between July 2000 and July 2005, 200 patients were allocated into either the DP or MVP arm. The survival time at 2 years, a primary end point, was favorable to the DP arm (P = .059 by a stratified log-rank test as a planned analysis and P = .044 by an early-period, weighted log-rank as an unplanned analysis). There was a trend toward improved response rate, 2-year survival rate, median progression-free time, and median survival in the DP arm (78.8%, 60.3%,13.4 months, and 26.8 months, respectively) compared with the MVP arm (70.3%, 48.1%, 10.5 months, and 23.7 months, respectively), which was not statistically significant (P > .05). Grade 3 febrile neutropenia occurred more often in the MVP arm than in the DP arm (39% v 22%, respectively; P = .012), and grade 3 to 4 radiation esophagitis was likely to be more common in the DP arm than in the MVP arm (14% v 6%, P = .056). CONCLUSION DP chemotherapy combined with concurrent TRT is an alternative to MVP chemotherapy for patients with LA-NSCLC.
Collapse
Affiliation(s)
- Yoshihiko Segawa
- Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital, Kitaku, Okayama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Kawahara M, Komuta K, Yoshioka H, Kawasaki M, Fujita Y, Yonei T, Ogushi F, Kubota K, Yamanaka T, Furuse K. Randomized phase II study of carboplatin plus either docetaxel (CbD) or paclitaxel (CbP) in Japanese patients with advanced non-small cell lung cancer (NSCLC): JMTO LC07-01. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Ueda Y, Matsuo K, Tsushima M, Mizuta M, Fujiwara K, Yonei T, Sato T. [Patient with autoimmune alveolar proteinosis who did not respond to GM-CSF inhalation therapy and underwent repeated whole-lung lavage]. Nihon Kokyuki Gakkai Zasshi 2009; 47:833-838. [PMID: 19827590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A 63-year-old man visited our department due to dry cough in September 2005. Chest radiography showed an infiltrative shadow extending from the bilateral hila to the peripheral areas. Chest CT scanning revealed a crazy-paving appearance. Bronchoalveolar lavage and transbronchial lung biopsy confirmed alveolar proteinosis. In addition, based on the absence of an underlying disease and a high titer of anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody, a diagnosis of autoimmune alveolar proteinosis was made. His course was observed on an outpatient basis because of mild symptoms, but dyspnea on exertion gradually increased. In July 2007, GM-CSF inhalation therapy was initiated in another hospital, but no improvement was observed. In November of the same year, he underwent whole-lung lavage for one lung followed by that for the other at our department. The symptoms rapidly improved after the lavage but were aggravated again after 6 months. In May 2008, whole-lung lavage was performed again. There have been no reports of adults with autoimmune alveolar proteinosis who did not respond to GM-CSF inhalation therapy and who underwent whole-lung lavage twice. GM-CSF inhalation therapy for autoimmune alveolar proteinosis is a pathogenesis-based epoch-making therapy, but the response rate is about 60%. In patients with treatment-resistant autoimmune alveolar proteinosis showing repeated aggravation of symptoms, whole-lung lavage under general anesthesia is a reliable therapeutic method.
Collapse
Affiliation(s)
- Yusuke Ueda
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
| | | | | | | | | | | | | |
Collapse
|
14
|
Asano M, Matsuo K, Ueda Y, Tsushima M, Mizuta M, Fujiwara K, Yonei T, Sato T. [Pulmonary carcinomatous lymphangiosis from recurrent breast cancer 10 years after resection of the primary tumor]. Nihon Kokyuki Gakkai Zasshi 2009; 47:602-607. [PMID: 19637802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A 55-year-old woman had a history of left mastectomy due to early breast cancer in 1998. She had been suffering from dyspnea on effort and dry cough since August in 2007, and visited our hospital 6 months later because the symptoms had been becoming worse. She was hypoxic and her chest radiograph showed bilateral diffuse shadows, so she was hospitalized. The specimen of transbronchial lung biopsy showed undifferentiated adenocarcinoma cells in lymphatics identified by lymphatic endothelium antibody D2-40 stain, so we diagnosed carcinomatous lymphangiosis. It also revealed the cells staining positive for Cytokeratin 7, negative for Cytokeratin 20, and positive for both estrogen receptor and progesterone receptor. These features were identical to the immunohistological findings of the specimen from the previously resected breast cancer. Chemotherapy with docetaxel was effective and improved her respiratory condition and the chest radiograph. The immunohistological findings are useful for diagnosis and selection of cancer therapy. We cannot find any case reports of recurrence with carcinomatous lymphangiosis over 10 years after resection of breast cancer in Japan. We must keep in mind that some cancers relapse after a long disease-free interval.
Collapse
Affiliation(s)
- Michiko Asano
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Tsushima M, Matsuo K, Mizuta M, Ueda Y, Fujiwara K, Yonei T, Yamadori I, Sato T. [Pleomorphic carcinoma of the lung with uncommon initial manifestation of intestinal perforation]. Nihon Kokyuki Gakkai Zasshi 2009; 47:507-511. [PMID: 19601528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A 47-year-old woman suddenly developed abdominal pain and visited the emergency room of our hospital. Chest and abdominal CT scan revealed free air in the abdominal cavity and a bulky pulmonary tumor in the right middle lobe. The perforated sigmoid colon was removed in an emergency operation. Histological examination of the resected tissue revealed undifferentiated carcinoma, but the histological differentiation could not be determined. We used immunohistochemical staining to distinguish primary non-small cell lung cancer from colon cancer; the resected tumor was positive for TTF-1 and CK7, but negative for CK20. Therefore, by using immunohistochemical staining we could diagnose the tumor of the large intestine as metastasis from non-small cell lung cancer. After the operation, systemic chemotherapy with carboplatin and docetaxel was repeated, but the lung tumor did not regress and the patient died. Autopsy examination confirmed the histology of the lung tumor as pleomorphic carcinoma. Morphological characteristics and the immunohistochemical staining pattern of the pulmonary tumor were consistent with that of the colon tumor. In Japan, this is the first report in which the initial manifestation of lung cancer was perforation of the large intestine due to metastasis.
Collapse
Affiliation(s)
- Mizuho Tsushima
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 2009; 45:1950-8. [PMID: 19231158 DOI: 10.1016/j.ejca.2009.01.023] [Citation(s) in RCA: 264] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2008] [Revised: 01/14/2009] [Accepted: 01/16/2009] [Indexed: 12/13/2022]
Abstract
We examined the impact of pretreatment neutrophil count on survival in patients with advanced non-small-cell lung cancer (NSCLC). A total of 388 chemo-naïve patients with stage IIIB or IV NSCLC from a randomised controlled trial were evaluated. The effects of pretreatment peripheral blood neutrophil, lymphocyte and monocyte counts and neutrophil-lymphocyte ratio on survival were examined using the proportional hazards regression model to estimate hazard ratios after adjustment for covariates. The optimal cut-off value was determined by proportional hazards regression analysis with the minimum P-value approach and shrinkage procedure. After adjustment for prognostic factors, the pretreatment elevated neutrophil count was statistically significantly associated with short overall (P=0.0008) and progression-free survival (P=0.024), whereas no association was found between prognosis and lymphocyte or monocyte count. The cut-off value selected for neutrophil count was 4500 mm(-3) (corrected hazard ratio, 1.67; 95% confidence interval (CI), 1.09-2.54). The median survival time was 19.3 months (95%CI, 16.5-21.4) for the low-neutrophil group (4500 mm(-3), n=204) and was 10.2 months (95%CI, 8.0-12.3) for the high-neutrophil group (4500 mm(-3), n=184). We confirmed that pretreatment elevated neutrophil count is an independent prognostic factor in patients with advanced NSCLC receiving modern chemotherapy. Neutrophil count is easily measured at low cost, and it may be a useful indicator of patient prognosis.
Collapse
Affiliation(s)
- Satoshi Teramukai
- Department of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto 606-8507, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Rai K, Matsuo K, Yonei T, Sato T. [Treatment-refractory-dental-extraction-associated pyothorax involving infection by 2 species of oral originated bacteria requires surgical debridement by video assisted thoracoscopic surgery (VATS)]. Kansenshogaku Zasshi 2008; 82:461-465. [PMID: 18975591 DOI: 10.11150/kansenshogakuzasshi1970.82.461] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Cases of septic pulmonary embolism (SPE) diagnosed clinically by CT after dental extraction rarely include verification of bacteria from the local infection site. We report the case of a 70-year-old man without background disease suffering severe pyothrax after dental extraction. We detected two species of oral bacteria from his pleural effusion. Treatment was so difficult that it required surgical debridement by video assisted thoracoscopic surgery (VATS), even after the appropriate administration of antibiotics. According to the American Heart Association (AHA) prophylaxis guidelines for preventing infective endocarditis indicate that it is uncommon to prescribe antibiotics to patients without background disease after dental extraction. No appropriate Japanese guidelines exist considering the prevention of SPE causing severe pyothorax as in our case. The hematogenous spread of bacteria such as SPE caused by sepsis after tooth extraction thus requires more attended careful consideration in clinical practice if patients are to be properly protected against potentially serious complications.
Collapse
Affiliation(s)
- Kammei Rai
- Department of Respiratory Organ, National Hospital Organization Okayama Medical Center
| | | | | | | |
Collapse
|
18
|
Hotta K, Kiura K, Takigawa N, Kuyama S, Segawa Y, Yonei T, Gemba K, Aoe K, Shibayama T, Matsuo K, Kamei H, Fujiwara Y, Bessho A, Moritaka T, Sugimoto K, Tabata M, Ueoka H, Tanimoto M. Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. J Cancer Res Clin Oncol 2008; 135:117-23. [DOI: 10.1007/s00432-008-0431-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2008] [Accepted: 05/23/2008] [Indexed: 10/21/2022]
|
19
|
Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer. Cancer Chemother Pharmacol 2007; 60:1-6. [PMID: 17393168 DOI: 10.1007/s00280-006-0336-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2006] [Accepted: 08/20/2006] [Indexed: 11/29/2022]
Abstract
PURPOSE The aim of this trial was to investigate the efficacy and safety of cisplatin (P) and irinotecan (I) (PI) alternating with doxorubicin (A), cyclophosphamide (C) and etoposide (E) (ACE) in patients with extensive-disease small-cell lung cancer (ED-SCLC). PATIENTS AND METHODS Patients with previously untreated ED-SCLC were enrolled in this trial. In the first, third and fifth cycles, PI (P: 60 mg/m(2) on day 1; I: 60 mg/m(2)/day on days 1, 8 and 15) was administered, whereas ACE (A: 50 mg/m(2) on day 1; C: 750 mg/m(2) on day 1; E 80 mg/m(2)/day on days 1-3) was given in the second, fourth and sixth cycles. Each cycle was repeated every 4 weeks. At the end of six cycles, patients who had obtained a complete response were given prophylactic cranial irradiation. RESULTS In total, 28 patients were enrolled, of whom 27 were assessable for efficacy and safety. Objective responses, including 4 (15%) complete responses, were observed in 25 patients (93%). Median survival time was 12.9 months. The principal toxicity was myelosuppression; grade 4 neutropenia and thrombocytopenia were observed in 89 and 4%, respectively. Febrile neutropenia occurred in 30% of patients. Diarrhea was mild (grade 3-4; 4%). All toxicities were reversible and there were no treatment-related deaths. The mean percentage of the delivered doses, relative to the projected doses, of PI and ACE were 84.6 and 91.1%, respectively. CONCLUSIONS These results indicate the PI-ACE regimen to have promising activity against ED-SCLC with moderate toxicities.
Collapse
Affiliation(s)
- Masahiro Tabata
- Department of Medicine II, Okayama University Medical School, 2-5-1, Shikata-cho, Okayama, 700-8558, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Takigawa N, Kiura K, Segawa Y, Watanabe Y, Kamei H, Moritaka T, Shibayama T, Ueoka H, Gemba K, Yonei T, Tabata M, Shinkai T, Hiraki S, Takemoto M, Kanazawa S, Matsuo K, Tanimoto M. Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer. Br J Cancer 2006; 95:1142-4. [PMID: 17031394 PMCID: PMC2360581 DOI: 10.1038/sj.bjc.6603422] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0–4.9).
Collapse
Affiliation(s)
- N Takigawa
- Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Tabata M, Kozuki T, Ueoka H, Kiura K, Harita S, Tada A, Shibayama T, Takigawa N, Yonei T, Gemba K, Segawa Y, Kishino D, Tada S, Hiraki S, Tanimoto M. A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. Cancer Chemother Pharmacol 2006; 60:53-9. [PMID: 17009034 DOI: 10.1007/s00280-006-0346-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2006] [Accepted: 09/04/2006] [Indexed: 11/28/2022]
Abstract
PURPOSE We conducted a phase I/II study of triplet chemotherapy consisting of cisplatin (CDDP), docetaxel (DCT) and gemcitabine (GEM) in patients with advanced non-small-cell lung cancer (NSCLC). METHODS Fifty-three untreated patients with stage IIIB or IV NSCLC were enrolled. All drugs were given on days 1 and 8. The doses of CDDP and DCT were fixed at 40 mg/m(2) and 30 mg/m(2), respectively. In the phase I portion, a dose escalation study of GEM with starting dose of 400 mg/m(2) was conducted and primary objective in the phase II portion was response rate. RESULTS The maximally tolerated dose (MTD) and recommended dose (RD) of GEM were determined as 800 mg/m(2) because grade 3 non-hematological toxicity (liver damage, diarrhea, and fatigue) developed in three of nine patients evaluated at that dose level. In pharmacokinetic analysis, C (max) and AUC of dFdC and dFdU were increased along with the dose escalation of GEM. However, no relationship between pharmacokinetic parameters and toxicity or response was observed. Objective response rate was 34% and median survival time was 11.7 months. Though major toxicity was myelosuppression, there were no life-threatening toxicities. CONCLUSION These results indicate that this triplet chemotherapy is feasible and effective in patients with advanced NSCLC.
Collapse
Affiliation(s)
- Masahiro Tabata
- Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Takigawa N, Segawa Y, Kiura K, Tabata M, Ueoka H, Yonei T, Shibayama T, Takata I, Matsuo K, Tanimoto M. Secondary primary cancer in the long-term survivors with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7147 Background: Although concurrent chemoradiotherapy (CT/RT) is associated with increased survival for patients (pts) with locally advanced non-small cell lung cancer (NSCLC), long-outcomes beyond 5 years have not been fully analyzed. Methods: Between 1994 and 1999, we conducted two phase II studies examining concurrent CT/RT for treatment of surgically unresectable stage IIIA or IIIB NSCLC. One regimen consisted of three cycles of 5-fluorouracil 500mg/m2 and cisplatin 20mg/m2, days 1–5, every 4 weeks and concurrent hyperfractionated thoracic RT (1.25Gy twice daily, total 62.5–70Gy) [FP-TRT] (Segawa et al. BJC 82, 2000). The other consisted of docetaxel 40mg/m2 and cisplatin 40mg/m2, days 1, 8, 29 and 36 and concurrent thoracic RT (2Gy daily, total 60Gy) [DP-TRT] (Kiura et al. BJC 89, 2003). Long-term data is presented. Results: In 50 pts treated with FP-TRT, the median survival time (MST) was 1.6 years (yr; 95% confidential interval [CI]: 0.91 - 2.25 yr) by a median follow-up time of 10.4 yr and the actual 5 yr-survival rate was 30%. In 15 long-term survivors, 3 and 2 pts died due to primary NSCLC and secondary primary cancer (SPC), respectively, 1 was lost to follow-up, and 9 are still alive. In 42 pts treated with DP-TRT, the MST was 2.1 yr (95% CI: 0.82 - 2.48 yr) by a median follow-up time of 6.3 yr and the actual 5 yr-survival rate was 31%. In 13 long-term survivors, 1 pt died due to primary NSCLC, 1 died due to SPC, 1 was lost to follow-up, and 10 are still alive. Overall, 7 of 92 pts enrolled in these studies developed SPCs (2 NSCLC, 1 small cell lung cancer, 2 esophageal cancers, 2 gall bladder cancers) although no pts developed leukemia or myelodysplastic syndrome. An observed incidence rate of SPCs was 2356.1/100,000 (95% CI: 947.6 - 4856.0). Cumulative incidence was 5.8% (standard error [SE] 4.0%) at 5 yr, 10.0% (SE 5.6%) at 8 yr and 60.8% (SE 18.9%) at 10 yr. The median time from the beginning of CT/RT to the diagnosis of SPC was 9.6 yr (95% CI: 8.1 - 11.1 yr). Conclusions: Approximately 30% of pts survived more than 5 years after concurrent CT/RT, however, they were still at risk of dying from primary NSCLC. Occurrence of SPC in long-term survivors should be concerned in follow-up. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Takigawa
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - Y. Segawa
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - K. Kiura
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - M. Tabata
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - H. Ueoka
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - T. Yonei
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - T. Shibayama
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - I. Takata
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - K. Matsuo
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| | - M. Tanimoto
- Okayama University Hospital, Okayama, Japan; Shikoku Cancer Center, Matsuyama, Japan; Sanyo Hospital, Ube, Japan; Okayama Medical Center, Okayama, Japan; Minami-Okayama Medical Center, Tsukubo, Japan; Fukuyama Medical Center, Fukuyama, Japan; Aichi Cancer Center, Nagoya, Japan
| |
Collapse
|
23
|
Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Moritaka T, Shibayama T, Matsuo K, Kato K, Kanehiro A, Tanimoto Y, Matsuo K, Ueoka H, Tanimoto M. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2006; 11:417-24. [PMID: 16259873 DOI: 10.1097/00130404-200509000-00010] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
UNLABELLED Risk factors for the development of interstitial lung disease in patients with non-small cell lung cancer receiving gefitinib and the prognostic factors after interstitial lung disease development have not been established. The aim of this study was to retrospectively identify and evaluate these possible factors. PATIENTS AND METHODS We reviewed the clinical records and radiographs of 365 consecutive patients with non-small cell lung cancer who received gefitinib in West Japan between 2000 and 2003. RESULTS In total, 330 patients were eligible for interstitial lung disease evaluation, and 15 patients (4.5%) were finally confirmed to have developed interstitial lung disease by blinded expert review. Multivariate analysis revealed that preexisting pulmonary fibrosis, poor performance status, and prior thoracic irradiation were independent risk factors for interstitial lung disease, with odds ratios of 21.0 (95% confidence interval, 5.12-86.3, P < 0.0001), 9.70 (2.27-41.4, P = 0.001), and 4.33 (1.27-14.8, P = 0.019), respectively. Among the 15 patients who developed interstitial lung disease, eight have died of the condition. Short interval from the initiation of gefitinib treatment to the onset of interstitial lung disease, acute interstitial pneumonia pattern, and the presence of pre-existing pulmonary fibrosis were associated with poor prognosis. DISCUSSION Our results suggest the importance of patient selection for gefitinib treatment based on interstitial lung disease risk factors in the Japanese population identified.
Collapse
Affiliation(s)
- Katsuyuki Hotta
- Department of Medicine II, Okayama University Medical School, Okayama, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Hotta K, Ueoka H, Kiura K, Tabata M, Ogino A, Umemura S, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Tanimoto M. Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol 2006; 44:717-22. [PMID: 16227162 DOI: 10.1080/02841860500256215] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
We evaluated the safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer (NSCLC). We retrospectively compared toxicity, response and survival outcomes for gefitinib in patients aged 75 years or older (elderly group) with the same outcomes in patients aged younger than 75 years. In total, 350 patients were eligible for this analysis, of whom 92 were in the elderly group and 258 in the non-elderly group. In the elderly group, adverse events were generally mild to moderate and grade 3-4 adverse events were observed in 8 (9%) patients. The objective response rate (17 vs. 21% for elderly vs. non-elderly, respectively) and median survival time (7.6 vs. 9.3 months) were also similar in the two groups. Multivariate analysis revealed elderly patients with lower Brinkman index tended to be more sensitive to gefitinib (odds ratio: 4.57, 95% confidence interval: 0.91-22.72, p = 0.0642). In this study, treatment with gefitinib appeared to be as safe and effective in elderly patients (aged 75 or older) with NSCLC as in non-elderly patients.
Collapse
MESH Headings
- Adenocarcinoma/drug therapy
- Adenocarcinoma/secondary
- Adenocarcinoma, Bronchiolo-Alveolar/drug therapy
- Adenocarcinoma, Bronchiolo-Alveolar/secondary
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents/therapeutic use
- Carcinoma, Large Cell/drug therapy
- Carcinoma, Large Cell/secondary
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Carcinoma, Non-Small-Cell Lung/secondary
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/secondary
- ErbB Receptors/antagonists & inhibitors
- Female
- Gefitinib
- Humans
- Lung Neoplasms/drug therapy
- Lung Neoplasms/pathology
- Male
- Middle Aged
- Quinazolines/therapeutic use
- Retrospective Studies
- Safety
- Survival Rate
- Treatment Outcome
Collapse
Affiliation(s)
- Katsuyuki Hotta
- Department of Medicine II, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, Bessho A, Tanimoto M. Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Ann Oncol 2005; 16:1817-23. [PMID: 16157622 DOI: 10.1093/annonc/mdi369] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND This study aimed to investigate the survival outcome of patients with non-small-cell lung cancer (NSCLC) who had obtained disease stabilisation with gefitinib treatment and to clarify the effect of continued treatment with gefitinib on prognosis. PATIENTS AND METHODS We reviewed the clinical records of 365 Japanese patients with NSCLC who received gefitinib (250 mg/day). RESULTS Of 324 (89%) patients assessable for response, 147 (45%) obtained disease stabilisation and 71 (22%) patients achieved an objective response. Overall survival in patients obtaining disease stabilisation was significantly longer than in patients with progressive disease (median survival time 12.1 versus 4.4 months; P <0.0001). In patients obtaining disease stabilisation, those who continued gefitinib treatment until disease progression tended to have longer overall and progression-free survival compared with those discontinuing gefitinib treatment (1-year survival rate 52.1% versus 36.6%, P = 0.08; 1-year progression-free survival rate 31.8% versus 5.2%, P = 0.001). Multivariate analysis showed discontinuing gefitinib was an independent risk factor for progression-free survival (hazard ratio 1.66; 95% confidence interval 1.07-2.56; P = 0.022) but not for overall survival. CONCLUSIONS Our findings indicate the importance of achieving disease stabilisation with gefitinib treatment and continued gefitinib treatment in Japanese patients with disease stabilisation, although further studies are required to confirm these findings.
Collapse
Affiliation(s)
- K Hotta
- Department of Medicine II, Okayama University Medical School, Okayama.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, Bessho A, Tanimoto M. Continued gefitinib treatment after disease stabilization prolongs survival of patients with advanced non-small-cell lung cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Hotta
- Okayama Univ, Okayama, Japan; Aichi Cancer Ctr Research Inst, Nagoya, Japan; Okayama Univ Medcl Sch, Okayama, Japan; Chugoku Central Hosp, Fukuyama, Japan; Okayama Rousai Hosp, Okayama, Japan; National Hosp Okayama Medcl Ctr, Okayama, Japan; National Shikoku Cancer Ctr Hosp, Matsuyama, Japan
| | - K. Matsuo
- Okayama Univ, Okayama, Japan; Aichi Cancer Ctr Research Inst, Nagoya, Japan; Okayama Univ Medcl Sch, Okayama, Japan; Chugoku Central Hosp, Fukuyama, Japan; Okayama Rousai Hosp, Okayama, Japan; National Hosp Okayama Medcl Ctr, Okayama, Japan; National Shikoku Cancer Ctr Hosp, Matsuyama, Japan
| | - H. Ueoka
- Okayama Univ, Okayama, Japan; Aichi Cancer Ctr Research Inst, Nagoya, Japan; Okayama Univ Medcl Sch, Okayama, Japan; Chugoku Central Hosp, Fukuyama, Japan; Okayama Rousai Hosp, Okayama, Japan; National Hosp Okayama Medcl Ctr, Okayama, Japan; National Shikoku Cancer Ctr Hosp, Matsuyama, Japan
| | - K. Kiura
- Okayama Univ, Okayama, Japan; Aichi Cancer Ctr Research Inst, Nagoya, Japan; Okayama Univ Medcl Sch, Okayama, Japan; Chugoku Central Hosp, Fukuyama, Japan; Okayama Rousai Hosp, Okayama, Japan; National Hosp Okayama Medcl Ctr, Okayama, Japan; National Shikoku Cancer Ctr Hosp, Matsuyama, Japan
| | - M. Tabata
- Okayama Univ, Okayama, Japan; Aichi Cancer Ctr Research Inst, Nagoya, Japan; Okayama Univ Medcl Sch, Okayama, Japan; Chugoku Central Hosp, Fukuyama, Japan; Okayama Rousai Hosp, Okayama, Japan; National Hosp Okayama Medcl Ctr, Okayama, Japan; National Shikoku Cancer Ctr Hosp, Matsuyama, Japan
| | - S. Harita
- Okayama Univ, Okayama, Japan; Aichi Cancer Ctr Research Inst, Nagoya, Japan; Okayama Univ Medcl Sch, Okayama, Japan; Chugoku Central Hosp, Fukuyama, Japan; Okayama Rousai Hosp, Okayama, Japan; National Hosp Okayama Medcl Ctr, Okayama, Japan; National Shikoku Cancer Ctr Hosp, Matsuyama, Japan
| | - K. Gemba
- Okayama Univ, Okayama, Japan; Aichi Cancer Ctr Research Inst, Nagoya, Japan; Okayama Univ Medcl Sch, Okayama, Japan; Chugoku Central Hosp, Fukuyama, Japan; Okayama Rousai Hosp, Okayama, Japan; National Hosp Okayama Medcl Ctr, Okayama, Japan; National Shikoku Cancer Ctr Hosp, Matsuyama, Japan
| | - T. Yonei
- Okayama Univ, Okayama, Japan; Aichi Cancer Ctr Research Inst, Nagoya, Japan; Okayama Univ Medcl Sch, Okayama, Japan; Chugoku Central Hosp, Fukuyama, Japan; Okayama Rousai Hosp, Okayama, Japan; National Hosp Okayama Medcl Ctr, Okayama, Japan; National Shikoku Cancer Ctr Hosp, Matsuyama, Japan
| | - A. Bessho
- Okayama Univ, Okayama, Japan; Aichi Cancer Ctr Research Inst, Nagoya, Japan; Okayama Univ Medcl Sch, Okayama, Japan; Chugoku Central Hosp, Fukuyama, Japan; Okayama Rousai Hosp, Okayama, Japan; National Hosp Okayama Medcl Ctr, Okayama, Japan; National Shikoku Cancer Ctr Hosp, Matsuyama, Japan
| | - M. Tanimoto
- Okayama Univ, Okayama, Japan; Aichi Cancer Ctr Research Inst, Nagoya, Japan; Okayama Univ Medcl Sch, Okayama, Japan; Chugoku Central Hosp, Fukuyama, Japan; Okayama Rousai Hosp, Okayama, Japan; National Hosp Okayama Medcl Ctr, Okayama, Japan; National Shikoku Cancer Ctr Hosp, Matsuyama, Japan
| |
Collapse
|
27
|
Abstract
NSIP associated with primary lung cancer has been rarely reported. In the present report, three cases of histologically proven non-specific interstitial pneumonia (NSIP) associated with primary lung cancer are described. Importantly, in our 3 cases, interstitial pneumonia which is histologically proven to be NSIP was observed diffusely in both lungs. NSIP in these 3 cases responded to steroid therapy. However, 2 patients died from primary lung cancer and 1 patient died from progression of the interstitial pneumonia. Although the association between lung cancer and NSIP has been rarely documented, this combination was considered to be one of the paraneoplastic phenomena. The possible association between primary lung cancer and NSIP is discussed.
Collapse
|
28
|
Hotta K, Harita S, Bessho A, Yonei T, Gemba K, Aoe K, Tabata M, Kiura K, Ueoka H, Tanimoto M. Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7063] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Hotta
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - S. Harita
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - A. Bessho
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - T. Yonei
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - K. Gemba
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - K. Aoe
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - M. Tabata
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - K. Kiura
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - H. Ueoka
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| | - M. Tanimoto
- Okayama University Medical School, Okayama, Japan; Chugoku Central Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; National Okayama Medical Center, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; National Sanyo Hospital, Ube, Japan
| |
Collapse
|
29
|
Yonei T, Ueoka H, Sato T, Kiura K, Tabata M, Kuyama S, Segawa Y, Harita S, Hiraki S, Tanimoto M. Cisplatin plus irinotecan (PI) alternating with a three-drug combination of doxorubicin, cyclophosphamide and etoposide (ACE) in patients with extensive-stage small-cell lung cancer (ED-SCLC): A phase II study of Okayama Lung Cancer Study Group (OLCSG). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7313] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Yonei
- National Okayama Medical Center, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Chuoh Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; Okayama Red Cross Hospital, Okayama, Japan
| | - H. Ueoka
- National Okayama Medical Center, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Chuoh Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; Okayama Red Cross Hospital, Okayama, Japan
| | - T. Sato
- National Okayama Medical Center, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Chuoh Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; Okayama Red Cross Hospital, Okayama, Japan
| | - K. Kiura
- National Okayama Medical Center, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Chuoh Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; Okayama Red Cross Hospital, Okayama, Japan
| | - M. Tabata
- National Okayama Medical Center, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Chuoh Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; Okayama Red Cross Hospital, Okayama, Japan
| | - S. Kuyama
- National Okayama Medical Center, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Chuoh Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; Okayama Red Cross Hospital, Okayama, Japan
| | - Y. Segawa
- National Okayama Medical Center, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Chuoh Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; Okayama Red Cross Hospital, Okayama, Japan
| | - S. Harita
- National Okayama Medical Center, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Chuoh Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; Okayama Red Cross Hospital, Okayama, Japan
| | - S. Hiraki
- National Okayama Medical Center, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Chuoh Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; Okayama Red Cross Hospital, Okayama, Japan
| | - M. Tanimoto
- National Okayama Medical Center, Okayama, Japan; Okayama University Hospital, Okayama, Japan; Chugoku Chuoh Hospital, Fukuyama, Japan; National Shikoku Cancer Center Hospital, Matsuyama, Japan; Okayama Red Cross Hospital, Okayama, Japan
| |
Collapse
|
30
|
Nogami N, Harita S, Ueoka H, Yonei T, Kiura K, Kamei H, Tabata M, Segawa Y, Gemba K, Tanimoto M. Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 45:85-91. [PMID: 15196738 DOI: 10.1016/j.lungcan.2003.12.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2003] [Revised: 12/12/2003] [Accepted: 12/16/2003] [Indexed: 11/21/2022]
Abstract
The role of non-platinum combination chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC) has not yet been clarified. In this phase I study, the dose-limiting toxicity (DLT), the maximum tolerable dose (MTD) and the antitumor activity of a two-drug combination of docetaxel (DCT) and irinotecan (CPT) in patients with advanced NSCLC were evaluated. Previously untreated patients with NSCLC in stage IIIB with malignant pleural effusion or stage IV were eligible. Both drugs were administered by 1-h intravenous infusion on day 1, and repeated every 3 weeks. DCT was given before CPT administration. Five escalating dose levels of DCT/CPT (40/135, 50/135, 50/150, 60/150, and 60/165 mg/m2) were studied. Eighteen patients received 44 courses. The DLT was considered to be neutropenia, because grade 4 neutropenia lasting for 3 days or more was observed in three patients, which was accompanied with three episodes of febrile neutropenia. As a non-hematological toxicity, grade 3 diarrhea occurred in three patients. Since all the three patients treated at the fifth dose level (DCT at 60 mg/m2 and CPT at 165 mg/m2) experienced DLT (grade 4 neutropenia in two patients and grade 3 hepatic toxicity in one), this dose level was determined to be the MTD. The objective response rate was 33.3%, and the median survival time was 13.6 months. To confirm the effectiveness of this combination for advanced NSCLC which was suggested in the present study, a phase II study with the recommended doses (150 mg/m2 for CPT and 50-60 mg/m2 for DCT) is warranted.
Collapse
Affiliation(s)
- Naoyuki Nogami
- Department of Internal Medicine II, Okayama University Medical School, 2-5-1 Shikatacho, Okayama, Okayama Prefecture 700-8558, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Segawa Y, Ueoka H, Kiura K, Tabata M, Takigawa N, Hiraki Y, Watanabe Y, Yonei T, Moritaka T, Hiyama J, Hiraki S, Tanimoto M, Harada M. Phase I/II study of altered schedule of cisplatin and etoposide administration and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small-cell lung cancer. Lung Cancer 2003; 41:13-20. [PMID: 12826307 DOI: 10.1016/s0169-5002(03)00139-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
To improve the efficacy of a combination of cisplatin and etoposide and concurrent accelerated twice-daily thoracic radiotherapy against limited-stage small-cell lung cancer, we conducted a phase I/II study using an altered schedule of chemotherapy administration. Chemotherapy consisted of four cycles of cisplatin (days 1 and 8) and etoposide (days 1, 2, 8, and 9) every 4 weeks. Accelerated hyperfractionated thoracic radiation (1.5 Gy twice daily x 30 fractions, total dose of 45 Gy) was concurrently given with the first cycle of chemotherapy. The recommended doses of cisplatin and etoposide determined in the phase I study were 40 and 80 mg/m(2), respectively. In the phase II study, the overall response rate was 100% (complete response: 32%, partial response: 68%). By a median follow-up time of 29 months, median radiation-outfield progression-free survival was 13.4 months, while radiation-infield progression-free survival did not reach median value. The median overall survival time was 22.9 months, with survival rate of 48.4% at 2 years. Major toxicities were leukopenia and neutropenia (>/=grade 3, 92% each). The local control and overall survival demonstrated in this study were excellent. However, the insufficient distant control suggests a need for development of more active chemotherapy regimens.
Collapse
Affiliation(s)
- Yoshihiko Segawa
- Department of Internal Medicine, National Shikoku Cancer Center, 13 Horinouchi, Matsuyama, Ehime 790-0007, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Kawada K, Yonei T, Ueoka H, Kiura K, Tabata M, Takigawa N, Harada M, Tanimoto M. Comparison of chemosensitivity tests: clonogenic assay versus MTT assay. Acta Med Okayama 2002; 56:129-34. [PMID: 12108583 DOI: 10.18926/amo/31714] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
When the development of chemotherapeutic agents reaches the clinical trial stage, it is necessary to perform drug sensitivity tests quickly in order to select the most promising agents for the treatment of cancer. In order to assess the possibility of using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as a substitute for the human tumor clonogenic assay (HTCA), we evaluated the correlation between the results obtained by these 2 assays in 5 human lung cancer cell lines. The correlation coefficient between the results of the HTCA and the MTT assay was 0.673, indicating a relatively good correlation. The correlation was most prominent in platinum analogues (r = 0.939) and good in anthracyclines/anthracenedione (r = 0.611). However, no significant correlation was observed in vinca alkaloids, etoposide, irinotecan, SN-38 (an active metabolite of irinotecan), and rhizoxin. The results of the MTT assay showed a high degree of correlation with those of the HTCA in predicting the sensitivity of cancer cell lines to platinum analogues, and anthracyclines/anthracenedione. These results suggest that the MTT assay may be more convenient and quickly performed than the HTCA and can replace HTCA in evaluating the effects of anticancer agents, especially the platinum analogues and anthracyclines/anthracenedione.
Collapse
Affiliation(s)
- Kazuhiko Kawada
- Department of Internal Medicine II, Okayama University Medical School, Japan
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Miyake A, Inoue Y, Omori M, Yonei T, Sato T. [Pseudohypoparathyroidism presenting laryngospasm]. Nihon Naika Gakkai Zasshi 2001; 90:2282-3. [PMID: 11769527 DOI: 10.2169/naika.90.2282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A Miyake
- Department of Respiratory Medicine, Okayama National Hospital, Okayama
| | | | | | | | | |
Collapse
|
34
|
Yonei T, Watanabe K, Sato T, Yamadori I. [Induction of psoriasis by human recombinant granulocyte colony stimulating factor in a patient with small cell lung cancer]. Nihon Kokyuki Gakkai Zasshi 2001; 39:438-41. [PMID: 11530395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
A 70-year-old man with small cell lung cancer was admitted to our hospital. He received chemotherapy consisting of cisplatin plus etoposide with concurrent chest irradiation. Because the patient had leukocytopenia after the first course of chemotherapy, he was treated subcutaneously with filgrastim (human recombinant granulocyte colony stimulating factor, G-CSF). Three days later, he developed psoriasiform skin eruptions mainly on the surface of the chest radiation field. When filgrastim was replaced with lenograstim (G-CSF), the skin lesions improved. But, after a second course of chemotherapy, lenograstim caused generalized psoriasiform eruptions. The patient had no previous history of psoriasis or any pre-existing skin disease. A skin biopsy revealed a Munro microabscess and spongiform pustules of Kogoj, which are the findings characteristic of the pathology of psoriasis. The MEDLINE report search has revealed, this is the first report of induction of psoriasis by G-CSF in a patient with small cell lung cancer.
Collapse
Affiliation(s)
- T Yonei
- Department of Respiratory Medicine, Laboratory Medicine, National Okayama Medical Center, 1711-1 Tamasu, Okayama, 701-1192, Japan
| | | | | | | |
Collapse
|
35
|
Fujiwara K, Sato T, Yonei T, Genba K, Nogami N, Yamadori I. [A case of chronic hypersensitivity pneumonitis induced by shiitake mushroom spores]. Nihon Kokyuki Gakkai Zasshi 2000; 38:908-13. [PMID: 11244726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
A 73-year-old woman was admitted to our hospital with a low-grade fever, dry cough and dyspnea on exertion as the chief complaints. She had been a professional shiitake mushroom grower for 50 years. Three years before visiting our hospital, she had been suspected of having hypersensitivity pneumonitis as a result of chest X-ray examination, bronchoalveolar lavage and transbronchial lung biopsy performed at another clinic. No antigens were identified at that time, but prednisolone was administered. On admission to our hospital, chest radiography and chest computed tomography revealed an interstitial shadow with subpleural honey-combing in both lower lung fields. After steroid pulse therapy, dyspnea on exertion and hypoxia improved moderately. Because of recurrence of the dyspnea, however, she was admitted on four separate occasions. On the second admission, an increase in lymphocytes was found by bronchoalveolar lavage, and septal lymphocytic infiltration accompanying fibrosis was demonstrated by transbronchial lung biopsy. On the fourth admission, a detailed immunological examination and an environmental survey were performed. The environmental provocation test yielded clinical symptoms similar to those experienced at the mushroom farm. Furthermore, tests of precipitation and lymphocyte proliferation in response to shiitake mushroom extracts were positive. Finally a diagnosis of chronic hypersensitivity pneumonitis induced by shiitake mushrooms was confirmed.
Collapse
Affiliation(s)
- K Fujiwara
- Department of Respiratory Medicine, Laboratory Medicine, Okayama National Hospital, 2-13-1 Minamigata, Okayama, 700-8566, Japan
| | | | | | | | | | | |
Collapse
|
36
|
Takata I, Ueoka H, Kiura K, Hiraki S, Eguchi K, Okimoto N, Harita S, Yonei T, Kamei H, Segawa Y, Shibayama T, Hiyama J, Harada M. Fractionated administration of cisplatin (CDDP) and irinotecan (CPT-11) in patients with stage IIIB and IV non-small-cell lung cancer (NSCLC): A phase II study. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80239-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
37
|
Ueoka H, Tabata M, Kiura K, Shibayama T, Gemba K, Segawa Y, Chikamori K, Yonei T, Hiraki S, Harada M. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. Br J Cancer 1999; 79:984-90. [PMID: 10070901 PMCID: PMC2362688 DOI: 10.1038/sj.bjc.6690157] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m(-2) and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m(-2), and the dose was escalated by an increase of 10 mg m(-2). The maximally tolerated dose of CPT-11 was determined as 60 mg m(-2) because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m(-2) and 60 mg m(-2) respectively.
Collapse
Affiliation(s)
- H Ueoka
- Second Department of Medicine, Okayama University Medical School, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
Bone mass, bone metabolic markers, and calcium regulation hormones were measured in members of an Antarctic wintering team who stayed at the Japanese Antarctic station, Syowa (latitude: south 69 degrees 00', longitude: east 39 degrees 35') for 1 year. Subjects included 31 healthy Japanese males, aged 24-51 years (mean age 34.5 years) at the beginning of this study, ingesting 488 IU/day of vitamin D and 550.9 mg/day of calcium per person. The long-term coefficient of variation (CV) of the equipment used in the assessments of bone mass was 0.67% in single X-ray absorptiometry (SXA), 0.17% in the speed of sound (SOS) by quantitative ultrasound method (QUS), and 0.63% in broadband ultrasound attenuation (BUA) by QUS. The seasonal changes in the calcaneal bone mineral density (BMD) by SXA were not significant, whereas the SOS measured by QUS decreased during the measurement period (0.55%, p < 0.001), and BUA increased (1.9%, p < 0.01). Bone-specific alkaline phosphatase and osteocalcin levels increased significantly during summer (p < 0.001) and urinary calcium level decreased significantly during winter (p < 0.05). Urinary pyridinoline and deoxypyridinoline levels decreased significantly at the end of winter (p < 0.001). Serum 1,25(OH)2D3 level did not change significantly, whereas serum 25(OH)D3 level decreased significantly during winter (p < 0.001). Serum parathyroid hormone (PTH) level significantly increased at the end of winter (p < 0.01), although both PTH level and 25(OH)D3 level remained within the normal range. We concluded that the 25(OH)D3 level in subjects who stayed in Antarctica for 1 year decreased significantly with the reduction in duration of sunshine, but there were no clear changes in bone mass.
Collapse
Affiliation(s)
- T Yonei
- Department of Orthopedic Surgery, Faculty of Medicine, Tottori University, Yonago, Japan
| | | | | | | |
Collapse
|
39
|
Ohke M, Yamadori I, Yuzurio S, Aoe K, Ozaki S, Kimura K, Yonei T, Kishimoto T. [A case of lung cancer with pericardial effusion without cardiac tamponade]. Nihon Kokyuki Gakkai Zasshi 1998; 36:77-80. [PMID: 9611981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Cardiac tamponade as an initial manifestation of primary lung cancer is uncommon. All such cases had shown symptoms of cardiac tamponade at the first visit of the hospital. We report a case of lung cancer with pericardial effusion without cardiac tamponade. Echocardiography, revealed little pericardial effusion and it has not increased for 3 months. Pericardiotomy revealed adenocarcinoma and lung cancer was confirmed by bronchial biopsy. It is necessary to further examine patients with even slight amounts of pericardial effusion.
Collapse
Affiliation(s)
- M Ohke
- Department of Internal Medicine, Okayama Rousai Hospital, Japan
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Kishimoto T, Okahara M, Chikamori K, Ozaki S, Aoe K, Ohke M, Fujioka H, Kimura K, Yonei T. [Clinical evaluation of benign asbestos pleurisy]. Nihon Kokyuki Gakkai Zasshi 1998; 36:18-22. [PMID: 9611971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Seventeen cases of benign asbestos pleurisy were evaluated clinically. All cases were male and almost all cases were more than 60 years-old. Most cases presented with chief complaints of chest pain and dyspnea, but 2 cases had no complaints. Pleural effusion appeared predominantly in the right side. Six cases had 2 or 3 episodes of pleural effusion, and 1 case had 5. Ten cases had an occupational history of asbestos exposure in shipyards and 5 other cases had a history in building construction. Almost all cases had more than 30 years of exposure to asbestos and benign asbestos pleurisy appeared after more than 30 years from the first exposure to asbestos. Among the patients, 6 cases had diffuse pleural thickening and 2 cases had malignancies. Pleural fluid was bloody in 14 of 17 cases (82%) and all pleural fluid showed an exudate. Lymphocytes represented 70% and eosinophils 15% of the cellular population of the pleural fluid. Hyaluronic acid in pleural fluid in cases of benign asbestos pleurisy averaged 29.5 micrograms/ml, which was significantly (p < 0.05) lower than in malignant pleural mesothelioma. Leukocytosis in peripheral blood and a high CRP value were uncommon in benign asbestos pleurisy.
Collapse
Affiliation(s)
- T Kishimoto
- Department of Internal Medicine, Okayama Rousai Hospital, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Sunami K, Kishimoto T, Yonei T, Ozaki S, Kimura K, Fujioka H, Ohke M, Ohnoshi T. [Clinical evaluation of 201TI single photon emission computed tomography in patients with large opacities due to silicosis with bronchogenic carcinoma]. Nihon Kyobu Shikkan Gakkai Zasshi 1996; 34:659-64. [PMID: 8741531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
201T1 single photon emission computed tomography (201T1 SPECT) was used to evaluate 18 patients with large opacities due to silicosis and 22 others with bronchogenic carcinoma. An early scan and a delayed scan were obtained and the retention index was calculated from the early ratio and the delayed ratio. In patients with silicosis, the retention index and the two ratios were significantly lower than in the patients with bronchogenic carcinoma (p < 0.01). In patients with stable shadows on chest X-ray films due to large opacities of silicosis, the delayed ratio was the same as or lower than the early ratio. However, in patients with silicosis who had high activity in large opacities, the delayed ratio was higher than the early ratio. These results suggest that 201)T1 SPECT is useful for evaluating the activity of large opacities in patients with silicosis and for differentiating large opacities caused by silicosis from those caused by bronchogenic carcinoma.
Collapse
Affiliation(s)
- K Sunami
- Department of Internal Medicine, Okayama Rousai Hospital, Okayama
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Kishimoto T, Ohke M, Ozaki S, Fujioka H, Kimura K, Sunami K, Yonei T, Ohnoshi T. [Recurrence of the acute respiratory distress syndrome in a patient with liver cirrhosis and diabetes mellitus]. Nihon Kyobu Shikkan Gakkai Zasshi 1996; 34:586-91. [PMID: 8753119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The acute respiratory distress syndrome developed twice within 4 months in a patient with liver cirrhosis and diabetes mellitus. The diagnosis was made from the diffuse alveolar shadows seen on a chest X-ray film and a lung injury score of 3.3. The initial episode resolved quickly with steroid pulse therapy. The second episode resolved to some extent after the same therapy, but the patient died of hepatic and renal failure followed by acute pneumonia. The causes of the first and second episodes were considered to be different and the outcome depended on liver and kidney function. We report this case because the acute respiratory distress syndrome rarely occurs within 4 months.
Collapse
Affiliation(s)
- T Kishimoto
- Department of Internal Medicine, Okayama Rohsai Hospital, Japan
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Yonei T, Watarai S, Okada Y, Yasuda T, Tsuji T. Increased urinary excretion of non-albumin antigen detected with YO-2, a novel monoclonal antibody, in diabetic patients. Acta Med Okayama 1995; 49:153-9. [PMID: 7676846 DOI: 10.18926/amo/30404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Monoclonal antibodies were raised against urine proteins from diabetic patients. An antibody, YO-2, stained three protein bands with apparent molecular weights of 66, 49, and 36 kDa. These bands were not reactive with an anti-human albumin antibody. The urine levels of YO-2-reactive antigen in the normal control were 0.97 +/- 0.37 U/g-Cr (units per gram of urine creatinine) (mean +/- SD). Those of the normo-, micro-, and macroalbuminuric diabetic patients, respectively, were 1.38 +/- 1.36, 2.87 +/- 2.07, and 3.92 +/- 3.33 U/g-Cr. They were significantly higher in the micro- and macroalbuminuric patients. The urine levels of YO-2-reactive antigen had no significant correlation with the urine albumin levels and hemoglobin A1c. We concluded that; a) monoclonal antibody YO-2 recognized a non-albumin urine antigen increasingly excreted in diabetic patients with nephropathy, b) recent glycemic control of diabetes would not significantly affect the urinary excretion rate of YO-2-reactive antigen, and c) the excretion rate and probably the mechanism of YO-2-reactive protein differed from those of albumin. The urine levels of YO-2-reactive antigen could be a clinical marker of diabetic nephropathy.
Collapse
Affiliation(s)
- T Yonei
- First Department of Internal Medicine, Okayama University Medical School, Japan
| | | | | | | | | |
Collapse
|
44
|
Okada Y, Jin-no K, Ikeda H, Sakai N, Sotozono M, Yonei T, Nakanishi S, Moriwaki S, Tsuji T. Changes in the expression of sialyl-Lewisx, a hepatic necroinflammation-associated carbohydrate neoantigen, in human hepatocellular carcinomas. Cancer 1994; 73:1811-6. [PMID: 7907941 DOI: 10.1002/1097-0142(19940401)73:7<1811::aid-cncr2820730707>3.0.co;2-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND Malignant transformation of cells is associated with the change in their carbohydrate antigens. Sialyl-Lewisx (SLEX) is a necroinflammation-associated carbohydrate antigen (NICA) of liver cells, because it is newly expressed in chronic inflammatory liver diseases. The authors addressed whether this type of carbohydrate antigen shows cancer-associated changes. METHODS Expression of SLEX and its related structures was studied immunohistochemically using the well characterized monoclonal antibodies in 13 small and 6 advanced hepatocellular carcinomas (HCC). RESULTS SLEX was negative in 7 small HCC, which were well differentiated histologically. Both negative and positive cells were observed in 6 other small HCC. When positive, SLEX was expressed membranously or cytoplasmically. The membrane positive HCC cells were well differentiated. Cytoplasmic expression was observed in the less differentiated cells. The SLEX-negative cells were associated with any degree of differentiation. In six advanced HCC, the expression of SLEX could also be correlated with their histologic differentiation. HCC expressed sialyl-type 2 chain N-acetyllactosamine (2-NAcLc), but not 2-NAcLc, Lewisx, and Lewisy. CONCLUSIONS SLEX, a NICA, showed HCC-associated changes that were dependent on the levels of HCC cell differentiation. Suppression and reactivation of alpha 1-3fucosyl-transferase was a possible enzymatic basis for the observed changes.
Collapse
MESH Headings
- Adult
- Aged
- Antigens, CD/analysis
- Antigens, CD/genetics
- Antigens, Differentiation, Myelomonocytic/analysis
- Antigens, Differentiation, Myelomonocytic/genetics
- Antigens, Tumor-Associated, Carbohydrate/genetics
- Biomarkers, Tumor/analysis
- Biomarkers, Tumor/genetics
- Carcinoma, Hepatocellular/genetics
- Carcinoma, Hepatocellular/immunology
- Carcinoma, Hepatocellular/pathology
- Cell Membrane/immunology
- Cell Membrane/ultrastructure
- Cytoplasm/immunology
- Cytoplasm/ultrastructure
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Immunoglobulin M/analysis
- Lewis X Antigen/analysis
- Lewis X Antigen/genetics
- Liver/immunology
- Liver/pathology
- Liver Cirrhosis/genetics
- Liver Cirrhosis/immunology
- Liver Cirrhosis/pathology
- Liver Neoplasms/genetics
- Liver Neoplasms/immunology
- Liver Neoplasms/pathology
- Male
- Middle Aged
Collapse
Affiliation(s)
- Y Okada
- Department of Nutritional Science, Faculty of Health and Welfare Science, Okayama Prefectural University, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Okada Y, Sotozono M, Sakai N, Yonei T, Nakanishi S, Tsuji T. Fucosylated Thomsen-Friedenreich antigen in alpha-anomeric configuration in human gastric surface epithelia: an allogeneic carbohydrate antigen possibly controlled by the Se gene. J Histochem Cytochem 1994; 42:371-6. [PMID: 8308254 DOI: 10.1177/42.3.8308254] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
Human gastric surface epithelial cells display the ABH blood group antigens with the core structure of N-acetyllactosamine (NAcLc). Their expression is under the control of the secretor gene Se. The Thomsen-Friedenreich (T)-antigen (Gal beta 1-3GalNAc) is another core structure of the ABH antigens. We examined the gastric surface epithelial expression of T- and alpha 1-2 fucosylated T (FucT) histochemically with peanut agglutinin (PNA) and monoclonal antibody (MAb) MBr1, respectively. Eight of 24 individuals exhibited the PNA-reactive antigen (i.e., T-expressers) and others the MBr1-reactive antigen (i.e., FucT-expressers). alpha-L-fucosidase digestion of the FucT-positive tissues and beta-galactosidase digestion of the T-positive tissues, respectively, made them reactive with PNA and the antibody specific for GalNAc alpha-O-Ser/Thr. There was a remarkable correlation among reactivities with MBr1, Ulex europaeus lectin 1 (UEA1), and anti-Leb MAb CO-431. ABH blood group status had no correlation with this expression. We conclude that human gastric surface epithelial cells constitutionally synthesize T in alpha configuration (i.e., Gal beta 1-3GalNAc alpha-O-Ser/Thr) and that it was alpha 1-2 fucosylated only in the FucT-expressers. alpha 1-2 fucosylation of T is suggested to be regulated by the Se gene.
Collapse
Affiliation(s)
- Y Okada
- First Department of Internal Medicine, Okayama University Medical School, Japan
| | | | | | | | | | | |
Collapse
|
46
|
Yonei T, Ohnoshi T, Hiraki S, Ueoka H, Kiura K, Moritaka T, Shibayama T, Tabata M, Segawa Y, Takigawa N. Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens. Acta Med Okayama 1993; 47:233-41. [PMID: 8213217 DOI: 10.18926/amo/31552] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Antitumor activities of five platinum analogs, including cisplatin, carboplatin, 254-S, DWA2114R, and NK121, were compared using five human lung cancer cell lines and 19 tumor specimens obtained from lung cancer patients. The antitumor activity was evaluated by determining the ratio of the maximum tolerated dose of each drug to the 70% tumor growth inhibitory concentration in a colony assay. Cisplatin was the most potent agent, followed by 254-S and carboplatin. DWA2114R and NK121 were less potent than cisplatin and 254-S. Cross-resistance to adriamycin was also investigated using an adriamycin-resistant small cell lung cancer subline, SBC -3/ADM30. SBC-3/ADM30 was 1.7- to 4.0-fold more resistant to cisplatin, carboplatin, NK121, and DWA2114R, than was the parent line, SBC-3, and the subline was 2.0-fold more sensitive to 254-S. Using SBC-3, in vitro combination effects of etoposide and cisplatin, carboplatin, or 254-S were evaluated by the median-effect principle. Synergism was noted when cisplatin and etoposide were combined at a fixed molar ratio of 1:1. Combination of carboplatin and etoposide showed an additive effect. The combination of 254-S and etoposide was antagonistic at low concentrations, but was markedly synergistic at higher concentrations. These data suggested the efficacy of 254-S in the treatment of lung cancer.
Collapse
Affiliation(s)
- T Yonei
- Department of Respiratory Medicine, National Okayama Hospital, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Hino N, Higashi T, Ueki T, Nakatsukasa H, Ooguchi S, Ashida K, Fujio K, Takaki A, Yonei T, Hasui T. Disappearance of pulmonary metastases by OK-432 treatment in a case of hepatocellular carcinoma. Acta Med Okayama 1993; 47:289-92. [PMID: 7692705 DOI: 10.18926/amo/31549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
We report here a case of hepatocellular carcinoma (HCC) with multiple lung metastases, which were disappeared by treatment of OK-432. The patient was a 65-year-old man and was diagnosed in 1986 with a small (17 x 11 mm) HCC in the anterior-superior segment of the liver. A part of the right hepatic lobe including the tumor was surgically removed, and transarterial injections of adriamycin (10 mg/week) and subcutaneous injections of OK-432 (10 KE/week) were given. Two and a half years later, recurrence of HCC in the liver and its invasion to vena cava inferior (IVC) were found. OK-432 administration was then stopped and percutaneous ethanol injection therapy (PEIT) was performed 10 times. Six months later, the PEIT was effective and the liver tumor with IVC invasion diminished. However, multiple lung metastases were visible on roentgenograms of the chest, and serum alphafetoprotein (AFP) concentration increased to 50,000 ng/ml. The OK-432 treatment resumed. After 6 months of OK-432 treatment, the multiple lung metastases were disappeared and the serum AFP level decreased to 100 ng/ml. At present, the patient is surviving without any sign of recurrence in either the liver or the lung. The clinical course of this case suggests that OK-432 might have effectively treated lung metastases of HCC, although the exact mechanisms are at present unclear.
Collapse
Affiliation(s)
- N Hino
- First Department of Internal Medicine, Okayama University Medical School, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Ohnoshi T, Hiraki S, Fujii M, Ueoka H, Yonei T, Tamura M, Moritaka T, Mima Y, Horiguchi T, Kiura K. Mortality and morbidity in two-year disease-free survivors of small cell lung cancer after treatment with combination chemotherapy with or without irradiation. Acta Med Okayama 1993; 47:209-14. [PMID: 8397470 DOI: 10.18926/amo/31591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
We evaluated the long-term outcome of 148 patients with small cell lung cancer (SCLC) who had been entered into clinical trials of chemotherapy with or without thoracic and prophylactic cranial irradiation (PCI) between 1981 and 1987. Eighteen patients (12%) survived for 2 or more years. With a minimum follow-up of 4.5 years, 10 of the 18 patients who remained disease-free at 2 years are currently alive and free of SCLC. Seven of these 10 patients currently function as they did before diagnosis. However, three suffer from central nervous system changes of varying degrees in severity which appeared 2-3 years after PCI. Eight of the 18 patients who were disease-free at 2 years have died. Two died of isolated relapse in the brain at 3.6 and 4.2 years after initiation of chemotherapy. Five died of other malignancies while continuing their complete response to SCLC; two of non-small cell lung cancer, two of acute myelogenous leukemia, and one of hepatocellular carcinoma. Another patient died of an unrelated disease without any evidence of SCLC. A small but substantial proportion of patients who underwent intensive treatment will achieve long-term survival; however, these patients remain at higher risk for second cancers and late toxicities. Therefore, attention must be directed to defining the safest way to employ such treatment in the management of SCLC.
Collapse
Affiliation(s)
- T Ohnoshi
- Second Department of Medicine, Okayama University Medical School, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Takigawa N, Ohnoshi T, Ueoka H, Yonei T, Kiura K, Tabata M, Kodani T, Kamei H, Segawa Y, Shibayama T. [Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines]. Gan To Kagaku Ryoho 1993; 20:929-35. [PMID: 8387762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Using reverse transcription polymerase chain reaction, we determined mRNA expression of topoisomerase (topo) II alpha and beta in adriamycin- and etoposide-resistant small cell lung cancer sublines, SBC-3/ADM 100 and SBC-3/ETP. The expression of topo II alpha mRNA decreased substantially in SBC-3/ADM 100 and SBC-3/ETP as compared with the parent cell line, SBC-3; 0.71-fold in the former and 0.38-fold in the latter. Similarly, that of topo II beta mRNA decreased to an extent of 0.68-fold in SBC-3/ADM 100 and 0.28-fold in SBC-3/ETP as compared with the parent cell line. SBC-3/ADM 100 and SBC-3/ETP were highly resistant to topo II inhibitors such as daunorubicin, epirubicin, pirarubicin, mitoxantrone, and teniposide. However, SBC-3/ADM 100 showed a less resistance to aclarubicin, and SBC-3/ETP was as sensitive to the drug as was in the parent cell line. The resistance to topo II inhibitors excluding for aclarubicin might be partially explained by the decreased expression of topo II alpha and beta mRNA.
Collapse
Affiliation(s)
- N Takigawa
- Second Dept. of Medicine, Okayama University Medical School
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Ohnoshi T, Hiraki S, Ueda N, Fujii M, Machida K, Ueoka H, Yonei T, Kiura K, Kamei H, Segawa Y. Long-term results of combination chemotherapy with or without irradiation in small cell lung cancer: a 5- to 11-year follow-up. Intern Med 1993; 32:215-20. [PMID: 8392405 DOI: 10.2169/internalmedicine.32.215] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Between April 1981 and December 1987, 148 patients with newly diagnosed small cell lung cancer (SCLC) were treated using combination chemotherapy with or without thoracic irradiation and prophylactic cranial irradiation (PCI) in a series of cooperative therapeutic trials. With a minimum follow-up of 4.7 years, 13 (9%) patients survived and were free of SCLC. These included 11 (15%) of 76 patients with limited disease and two (3%) of 72 patients with extensive disease. Three died without any evidence of SCLC (one each from second leukemia, non-small cell lung cancer, and unrelated disease). The remaining 10 (7%) patients are currently alive and free of SCLC beyond 4.7 years. Since late relapse beyond 5 years is a very rare event, these patients may have been cured. However, late toxicity of PCI must be kept in mind. Three among the 10 patients have suffered from neuropsychologic symptoms of varying degrees in severity. Although the long-term survival rate is a benchmark in the treatment of SCLC, modifications of therapy that may potentially avoid such toxicities should be considered hereafter.
Collapse
Affiliation(s)
- T Ohnoshi
- Second Department of Medicine, Okayama University Medical School, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|